Formulary Search Results for: CALCIUM AND VITAMIN D
9.6.2 Vitamin B group - View Category
5.1.7 Some other antibacterials - View Category
Restrictions:
Restricted to use on the advice of local microbiologists and infectious disease specialists only in the following situations:
- in accordance with OPAT service clinical management pathway for second-line use or when meticillin-resistant Staphylococcus aureus (MRSA) infection is suspected AND when the patient is initially hospitalised due to ABSSSI, requires intravenous antibiotics, but is eligible for early discharge as soon as their medical condition does not require further inpatient treatment.
Prescribing Notes:
Please note: this is a PROTECTED ANTIBIOTIC (see policy here) and relevant paper work should be completed.
5.1.7 Some other antibacterials - View Category
Restrictions:
Restricted to specialist initiation by a microbiologist or specialist in infectious diseases. Restricted to use in patients not responding to or intolerant of a glycopeptide, or those with microbiological cultures which indicate glycopeptide resistance.
Prescribing Notes:
Please note, this is a PROTECTED ANTIBIOTIC (see policy here) and relevant paper work should be completed.
For daptomycin dosing in adults click here
5.1.7 Some other antibacterials - View Category
Restrictions:
Fidaxomicin is restricted to use for the treatment of adults with microbiologically proven recurrence of Clostridium difficile infection (CDI) only on the advice of Consultant microbiologists or Consultants in Infectious Diseases.
Please note: this is a PROTECTED ANTIBIOTIC (see policy here) and relevant paper work should be completed.
It is non-formulary for use in adults with first episode of CDI or as empirical treatment in CDI.
6.1.1.2 Intermediate- and long-acting insulins - View Category
Restrictions:
Insulin detemir (Levemir®) is restricted to use in adults with severe/ frequent nocturnal hypoglycaemia. Not for routine use in type 2 diabetes unless patients suffers from recurrent episodes of hypoglycaemia. Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
6.1.2.2 SGLT2 Inhibitors - View Category
Restrictions:
Type 2 diabetes mellitus:
Restricted to the treatment of type 2 diabetes in adult patients as:
- Monotherapy in adults for whom use of metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control only if a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed AND a sulfonylurea or pioglitazone is not appropriate
- Dual therapy in combination with metformin, when metformin alone with diet and exercise does not provide adequate glycaemic control and a sulfonylurea is inappropriate
- Triple therapy in combination with metformin and sulfonylurea, as an alternative to DPP-4 inhibitor
- In combination with insulin, when insulin with diet and exercise, does not provide adequate glycaemic control
Prescribing Notes:
NHSGGC Diabetes Guidelines click here
Please click hyperlinks for formulary information on use in chronic heart failure and chronic kidney disease.
6.1.2.2 SGLT2 Inhibitors - View Category
Restrictions:
Restricted to use only in adult patients for whom a combination of dapagliflozin and metformin is appropriate and who have demonstrated compliance issues with the separate constituents.
Prescribing Notes:
NHSGGC Diabetes Guidelines click here
6.1.2.3 Incretin mimetics - View Category
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes as part of a triple therapy in patients with inadequate glycaemic control on two oral anti-diabetic drugs.
Prescribing Notes:
- Dulaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name; the manufacturer advises to record the brand name and batch number after each administration.
- NHSGGC Diabetes Guidelines click here
6.1.2.3 Incretin mimetics - View Category
Restrictions:
Restricted to initiation by Consultant Diabetologists for use in patients who are uncontrolled on basal insulin analogues (glycosylated haemoglobin [HbA1c] >7.5% [59mmol/mol]) and for whom a GLP-1 receptor agonist is appropriate as an add-on intensification therapy to basal insulin to obtain glucose control.
Prescribing Notes:
- Liraglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name; the manufacturer advises to record the brand name and batch number after each administration.
- NHSGGC Diabetes Guidelines click here
6.1.2.3 Incretin mimetics - View Category
Restrictions:
Use in the treatment of type 2 diabetes mellitus (T2DM) is restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes for use in addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option.
Prescribing Notes:
- Semaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name; the manufacturer advises to record the brand name and batch number after each administration.
- NHSGGC Diabetes Guidelines click here